

Colorado Medication for Opioid Use Disorder Program Implementation Outcomes

Claudia R. Amura, PhD MPH¹, Aimee Techau, PMHNP-BC, CARN-AP¹, Ursula Hollins², Andrea Alvarez, RN³, Nancy Beste, MPAS PA-C CACII⁴, Emelin Martinez, FNP, MSN⁵, Kim Gonzalez⁶, Dayna DeHerrera-Smith, MPH^{4,7}, Rachel Stranathan, PAC⁸, Rosario Medina, PhD¹
¹University of Colorado College of Nursing, CO, ²Colorado Treatment Services, Pueblo, ³Health Solutions Inc., Pueblo, CO, ⁴Front Range Clinics Northwest, Steamboat Springs, CO, ⁵Valley Wide Health Systems, Alamosa, Colorado, ⁶Front Range Clinics, Wester Slope, ⁷Wide Health System, ⁸River Valley Health Clinics, Montrose & Delta, CO

Purpose

To evaluate the expansion of Medication Substance Used Disorder (MOUD) Program in rural Colorado and plans for sustainability


Background

- The US faces an opioid crisis, disproportionately affecting rural areas
- Under SB01, the Colorado Legislature funded the implementation of a Medication for opioid use disorder (MOUD) program to lower disparities and expand the nurse-led workforce to treat OUD throughout Colorado (Hub and Spoke System)
- A Hub and Spoke system of training and expertise has shown effectiveness in rural areas in other states

Methods


- MOUD lunched in 20 sites (8 grantees) in rural Colorado
- Organization and de-identified patient-level data collected monthly
- PRISM/RE-AIM framework to inform context, reach, adoption, implementation and plan for maintenance
- Addiction Severity Index used to measure OUD's impact across various life domains (health, substance use, social aspects).
- SWOT analyses with each grantee to inform sustainability plans

SB01 Colorado MOUD Expansion





Results

Patients




- Avg 36 y.o, not married (74%)
- Medicaid (86%)+
- Unemployed (46%), part-time (26%)
- Some Legal concerns (40%) parole (25%)
- Health less than average (83%); Pain (65%)
- Substance use in last mo: Opiates (77%), Heroin (69%), Alcohol (26%), Cannabis (48%); Meth (27%)
- Previous SU treatment (75%)
- Moderate Depression (53%)/Anxiety (57%)

COVID-19 Impact



MOUD Service Growth



TREATMENT	Methadone	Buprenorphine	Naltrexone
	38.70%	49.20%	9.50%

	period	CTS	HS	FRC-NE	FR-West	SLV-CMCC	LAH	River Valley	Provid.	TOTAL
Patients	Jan'20-Feb'21	349	203	62	118	215	73	72	23	1115
Providers current		3	6	3	3	28	15	9	0	67

Comprehensive SWOT Analysis

STRENGTHS	WEAKNESSES
<p>Pilot agencies: established clinic structure/ patient-centered services</p> <p>New grantees: Grow # providers to expand patient-centered services</p> <p>Partnership solidifying/growing; cover massive geographical areas</p> <p>Community partners: law enforcement/judicial/jails, schools</p> <p>Established case Manager/peer specialist to help patient navigation</p> <p>Establishing presence in the community</p> <p>Expert support from CU</p>	<p>Low retention of patient in MOUD treatment; no-shows are discouraging for providers</p> <p>Not all agencies in partnership offer BH for patients</p> <p>Most services centralized, and lack of unified system for patient follow up</p> <p>Inconsistency in EHR and policies and clinical guidelines across partners and systems</p> <p>Incompatible local tracking and program needed reporting</p> <p>Sites not prepared to provide remote services/telehealth</p>
OPPORTUNITIES	ENVIRONMENTAL CHALLENGES
<p>Develop further opportunities for telehealth initiated through the pandemic</p> <p>Continue to grow MAT service, behavioral health, community partnerships</p> <p>Continue training providers to coverage at each site and county serviced</p> <p>Leverage care coordination, peer support, resources (i.e. housing)</p> <p>Effective ways to ensure retention and re-engaging patients in relapse</p> <p>Move from induction to retention and harm-reduction</p> <p>Continue outreach to be known in the communities and lower stigma</p>	<p>Social challenges in patients (homeless, basic needs, hard to reach populations)</p> <p>COVID-19 impact on organization, services and patients (increase)</p> <p>Patients lack access to technology/service/coverage to engage in telehealth</p> <p>Stigma in the community</p> <p>Unreliable transportation and vast geography</p> <p>Polysubstance use on the rise: Meth, alcohol, marijuana, tobacco</p> <p>Unstable levels of funding, barriers for reimbursement</p>

Conclusion

- Legislation and academic-community collaboration allowed expansion of MOUD Program to > 20 rural counties
- Exponential growth since start of program at state level:
 - Access to services in geographically diverse areas
 - Reach a high need population
 - New providers, peer assistance, care coordination
- COVID-19 posed serious barriers in emerging care systems
- Capacity building and leveraging partnerships meant valuable lessons learned despite the COVID-19
- Acquired successful program templates for future expansions

Future Directions

- Ongoing advocacy for legislative support and to overcome health insurance and telehealth barriers
- Outreach and education to lower stigma
- Continue solidifying partnership and care coordination
- Systematically assess/address needs and public health impact
- Renewal funding for further MAT expansion in Colorado.

Bibliography

- Sorrell et al (2020) J. Subs Abuse Treatment. From Policy to Practice: Pilot Program Increases Access to Medication-Assisted Treatment in Rural Colorado.
- Colorado Health Institute (2018). "Death by Drugs: Colorado Reaches a Record High for Overdose Fatalities." <https://www.coloradohealthinstitute.org/research/death-drugs>.
- LaBelle, C. T., et al. (2016). Office-based opioid treatment with buprenorphine: statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treatment **60**: 6-13.
- McCraith MS et al. Using the Practical, Robust Implementation and Sustainability Model to qualitatively assess multilevel contextual factors to help plan, implement, evaluate, and disseminate health services programs. Transl Behav Med. 2019 Nov 25;9(6):1002-1011.

Funding

This study was funded by Colorado Senate Bill 19-001. Additional infrastructure support from the Colorado Clinical and Translational Science Institute, NIH/NCRR grant #UL1 RR025780. The authors have not financial disclosure related to this study